Zynerba Pharmaceuticals Provides 2018 Clinical and Corporate Update
January 03, 2018 16:30 ET
|
Zynerba Pharmaceuticals, Inc.
- Focusing Strategy on Rare and Near-Rare Neurological and Psychiatric Disorders - - Pediatric Neurologist Liza Squires, M.D. Joins as Chief Medical Officer - - Conference Call to be Held at 8:30...
Agile Therapeutics Inc. Hosts First Analyst Day Focused on Previewing its Corporate Vision and Commercial Strategy
October 10, 2017 18:38 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Oct. 10, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women’s healthcare company, today hosted the Company’s first analyst day in New York City to showcase its...
Zynerba Pharmaceuticals Announces Positive Top Line Results in ZYN002 Open Label Phase 2 FAB-C Study in Children with Fragile X Syndrome
September 28, 2017 06:30 ET
|
Zynerba Pharmaceuticals, Inc.
ZYN002 successfully met the primary endpoint and showed clinically meaningful improvements Zynerba to host conference call and webcast today, September 28 at 8:30 am ET DEVON, Pa., Sept. 28, 2017 ...
Agile Therapeutics Announces FDA Acceptance of the NDA Resubmission of Twirla®
July 27, 2017 16:11 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., July 27, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a forward-thinking women’s healthcare company, today announced that the U.S. Food and Drug Administration...
CURE Pharmaceutical Expects Increased Demand for Its Enhanced Transdermal Drug Delivery Platform
July 05, 2017 09:00 ET
|
CURE Pharmaceutical
OXNARD, Calif., July 05, 2017 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology and pharmaceutical cannabinoid molecule development...
Aequus Licenses Rights to Cannabinoid Transdermal Patch to Treat Neurological Disorders
March 02, 2017 08:00 ET
|
Aequus Pharmaceuticals
VANCOUVER, BC--(Marketwired - March 02, 2017) - Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company") announced today that through a previously announced Research...
Agile Therapeutics to Present at the RBC Capital Markets 2017 Global Healthcare Conference
February 14, 2017 16:00 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Feb. 14, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX) a women’s health specialty pharmaceutical company, announced today that its Chief Executive Officer, Al...
Agile Therapeutics Reports Second Quarter 2016 Financial Results
August 08, 2016 16:05 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's health specialty pharmaceutical company focused on the development and commercialization of new...
Agile Therapeutics Strengthens Executive Leadership Team with New Chief Commercial Officer
July 06, 2016 16:15 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., July 06, 2016 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's health specialty pharmaceutical company focused on the development and commercialization of...
Agile Therapeutics Announces Issuance of Patent for Progestin Patch Designs
June 16, 2016 08:00 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., June 16, 2016 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's health specialty pharmaceutical company focused on the development and commercialization of...